Qualification and quantification of plasma cell-free DNA after long-term storage conditions in patients with benign prostatic hyperplasia (BPH): a pilot study

Free DNA is used as a cancer biomarker due to its low cost, high applicability, and fast, reliable results compared to invasive methods. This study aimed to evaluate the quantification of plasma-free DNA after long-term storage conditions and perform qualification through single nucleotide polymorph...

Full description

Saved in:
Bibliographic Details
Published in:Journal of laboratory medicine 2022-12, Vol.46 (6), p.383-389
Main Authors: Bozkurt, Aliseydi, Gürbüzel, Mehmet, Sayar, Ilyas, Baydeniz, Soner, Arslan, Yusuf Kemal
Format: Article
Language:English
Subjects:
Biomarkers
ccat2
Deoxyribonucleic acid
DNA
free dna
Genetic testing
hras
Hyperplasia
Nucleotides
Peripheral blood
Plasma
Polymorphism
ret
single nucleotide polymorphism (snp)
Single-nucleotide polymorphism
Single-stranded DNA
Storage conditions
Thawing
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Free DNA is used as a cancer biomarker due to its low cost, high applicability, and fast, reliable results compared to invasive methods. This study aimed to evaluate the quantification of plasma-free DNA after long-term storage conditions and perform qualification through single nucleotide polymorphism (SNP) screening based on this DNA.Plasma-free DNA samples were quickly isolated from the peripheral blood of both the benign prostatic hyperplasia (BPH) and control group participants and then maintained at −80 °C for four years. Upon thawing, first, free DNA was purified and fluorometric measurements were taken to determine the amount of DNA. Subsequently, the rs6983267, rs12628, and rs1799939 SNPs were screened in the CCAT2, HRAS, and RET genes, respectively.Significant results were obtained from the fluorometric measurements in terms of single-stranded DNA (ssDNA) (p
ISSN:2567-9430
0342-3026
2567-9449
1439-0477
DOI:10.1515/labmed-2022-0044